US drug developer Novavax Inc mentioned on Tuesday it was doubling its potential Covid-19 vaccine manufacturing capability to 2 billion doses yearly below an settlement with Serum Institute of India, sending its shares up about 7 per cent.
In August, Novavax signed a take care of Serum Institute, the world’s largest producer of vaccines, to provide a minimal of 1 billion doses of its vaccine candidate, when authorised, for low- and middle-income international locations and India.
As a part of the expanded settlement, Serum Institute will even manufacture the antigen part of the vaccine, dubbed NVX-CoV2373, which Novavax mentioned will deliver its manufacturing capability to over two billion doses by mid-2021.
Novavax’s vaccine is at the moment in mid-stage trials after an early-stage research confirmed it produced excessive ranges of antibodies towards the novel coronavirus. The firm plans to start late-stage trials within the third quarter.
Last month, Novavax mentioned it is going to provide 60 million doses of its coronavirus vaccine candidate to the UK starting as early as the primary quarter of 2021.
The firm can also be making ready to ship 100 million doses to the United States by January after it was awarded $1.6 billion for its potential vaccine, and has additionally signed provide agreements with Canada and Japan.
Other drugmakers comparable to Pfizer Inc and Moderna Inc have already begun giant late-stage research of their experimental vaccines.
[Attribution Business Standard]